source
- Novartis and Bristol Myers pause multiple autoimmune CAR-T trials after serious immune adverse eventsNovartis and Bristol Myers Squibb announced a temporary halt to several CAR-T cell therapy trials targeting autoimmune diseases. The pause involves Novartis’s autologous CD19 CAR-T candidate rapca…
- Amgen faces FTC-backed lawsuit over patent-application purchase amid insurer disputeAmgen and a large health insurer are locked in a court fight over whether purchasing a drug patent application can be used to extend a monopoly on a medicine. The case is drawing attention because…